Research Article: Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma
Abstract:
Background: Disulfidptosis is an emerging type of programmed cell death related to ROS accumulation and aberrant disulfide bond formation. Multiple myeloma (MM) is the second most prevalent hematologic malignancy characterized by a high synthesis rate of disulfide bond-rich proteins and chronic oxidative stress. However, the relationship between disulfidptosis and MM is still unclear.
No summary available.